Charles River Laboratories (CRL) Tops Q1 EPS by 8c; Boosts FY16 EPS Outlook
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $288.50 --0%
Revenue Growth %: -4.3%
Financial Fact:
Loss from discontinued operations, net of tax: 342K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -4.3%
Financial Fact:
Loss from discontinued operations, net of tax: 342K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $0.98, $0.08 better than the analyst estimate of $0.90. Revenue for the quarter came in at $354.9 million versus the consensus estimate of $354.91 million.
GUIDANCE:
Charles River Laboratories sees FY2016 EPS of $4.32-$4.45, versus the consensus of $4.34.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
- GE Aerospace to acquire Consolidated Precision in $11.75b deal
- HSBC explains why risk assets continue to ignore every negative catalyst
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
